Nanobiotix (NASDAQ:NBTX) Shares Up 8.8% – Here’s What Happened

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) was up 8.8% during trading on Tuesday. The stock traded as high as $22.79 and last traded at $23.17. 3,785 shares were traded during mid-day trading, a decline of 96% from the average daily volume of 93,957 shares. The stock had previously closed at $21.30.

Analysts Set New Price Targets

A number of research analysts have weighed in on NBTX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday. Guggenheim began coverage on shares of Nanobiotix in a report on Tuesday, September 15th. They set a “buy” rating and a $64.00 target price for the company. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Nanobiotix has a consensus rating of “Moderate Buy” and a consensus price target of $46.67.

Nanobiotix Stock Up 13.9%

The firm’s fifty day simple moving average is $34.37 and its two-hundred day simple moving average is $36.59.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. Headquartered in France, the company uses its proprietary NanoXray technology to design nanoparticles intended to enhance the effects of radiotherapy within solid tumors.

Nanobiotix’s lead product candidate, NBTXR3, is an investigational radioenhancer composed of hafnium oxide nanoparticles. Administered directly into a tumor before radiotherapy, NBTXR3 is designed to increase energy deposition in cancer cells when exposed to X-rays, with the goal of improving tumor control while using established radiation-treatment techniques.

The company is evaluating NBTXR3 in clinical studies across several cancer indications, including locally advanced soft-tissue sarcoma and head and neck cancers, as well as other solid tumors.